|
The Non-Linearity Conundrum in Pharma Design
By Geoff Middleton | Pharmaceutical Online | December 2, 2016 In the pharmaceutical and biologics manufacturing community, we’ve been instilled with a unified and rigorous direction with respect to capital project execution. The emphasis is speed, and rightfully so. These projects are among the most complex and costly in facility construction; not to mention that, given the revenue at risk, the overarching focus on speed to market is undeniable. [READ ARTICLE] |
|
The Pharma Design Detour: Addressing Shortcuts In Facility Design
By Geoff Middleton | November 23, 2015 | Pharmaceutical Online Manufacturing facilities in the pharma industry may set the bar high for complexity and capital density when compared to the wider industrial community. At the very beginning of the design process, however, where the initial concepts are developed and decided upon, all too often a sense of urgency overtakes, leading to shortcuts in the process. However, two factors seem poised to change this pattern. [READ ARTICLE] |